# **GROW 22/1**



### **GROW 22/1**

Cannabis Based Medicinal Product (CBMP)
Approved for prescription use in the UK

**Grown by:** PHCann in North Macedonia

Active ingredient: Approx. 22% THC

<1% CBD

**Profile Type:** Sativa Dominant Hybrid


**Cultivar:** LA S.A.G.E.


Formulation: Flos: whole dried

Cannabis Flowers

Ingestion method: Inhaled via herbal vaporiser







Terpene	D-limonene	β-Myrcene	β-Caryophyllene	α-Humulene	β-Ocimene	Terpinolene
Scent	sweet fruity	woody fruity	woody spicy	spicy	floral	earthy woody

## **GROW 22/1**

#### **TITRATION GUIDE**

- There currently is no uniform starting dose for cannabis products nor uniform dosing information.
- Patients are recommended to slowly titrate up to find their optimal dose for maximal therapeutic effects and minimal adverse effects.
- Timing of onset depends on mode of administration.

#### Onset and duration of effects for inhalation and oral adminstration<sup>2</sup>

	Inhalation			Oral administration		
Onset of Effect	<u>.</u>	Within seconds to minutes	Ŀ	Within 30 minutes to 2 hours		
Peak effects	Ŀ	Full effects peak within 30 minutes	Ŀ	Full effects peak within 4 hours		
Duration of Effect	<u>L</u>	Up to 6 hours or longer	Ŀ	Up to 12 hours or longer		

<sup>2.</sup> Minister of Health HC, Health Canada. Health Effects of Cannabis.; 2017.

Adverse events should be reported. Reporting forms and information can be found at: www.mhra.gov.uk/yellowcard

Adverse events should also be reported to:

IPS Pharma | medicalcannabis@ipsspecials.com | 0800 644 0747



**Grow Group** | Suite A, 6 Honduras Street | London EC1Y 0TH | United Kingdom